-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Acute myeloid leukemia (AML) remains difficult to treat because of high genetic heterogeneity not only between different patients, but also between subclonal populations of cancer cells within the same patient
Now, in a new study, researchers from research institutions such as the University of Groningen in the Netherlands and the University of Barcelona in Spain have found that a key enzyme in glucose metabolism, pyruvate dehydrogenase kinase 1 (PDK1), is a key enzyme in leukemia stem cells containing a large number of leukemia stem cells.
PDK1: a determinant of different metabolic states
PDK1: a determinant of different metabolic statesIn the new study, PDK1 was identified as a determinant of different metabolic states
Integrated metabolomic, proteomic and transcriptomic analysis of major energy flows in AML and normal hematopoietic stem/progenitor cells
Image via Nature Communications, 2022, doi:10.
The authors applied metabolomic, proteomic, genomic and transcriptomic techniques, as well as gene ontology and gene set enrichment analysis (GSEA), among others
These findings also indicate that inhibition of PDK1 induces mitochondrial stress and improves the efficacy of glutaminase inhibitor-based antitumor therapies
Note: The original text has been deleted
References:
Ayşegül Erdem et al.